Skip to content

Clinical efficacy of autologous cell transplantation combined with 308nm SQ LED light in treatment of stable refractory vitiligo

Clinical efficacy of autologous cell transplantation combined with 308nm SQ LED light in treatment of stable refractory vitiligo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091169
Enrollment
Unknown
Registered
2024-10-22
Start date
2023-11-02
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Interventions

Test group:Pre transplant illumination+transplant+post transplant illumination
Control group:Transplantation+Light exposure after 3 months of transplantation

Sponsors

People's Hospital of Xinjiang Uygur Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. According to the above diagnostic criteria, clearly diagnosed as patients with stable vitiligo; 2. all have more than 6 months of conventional treatment (oral, topical drugs or traditional phototherapy, etc.) is not effective; 3. Age 5-70 years old, men and women are not limited; 4. have not used corticosteroids, calcium-modulated neural phosphatase inhibitors and antioxidants and other topical drugs in the last 1 month; 5. No localized skin lesions or generalized skin have received any phototherapy, including PUVA, NB-UVB, etc. in the last 1 month; 6. All patients have good compliance and can be followed up as scheduled; 7. Agreed to videotape the skin lesions and voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women, or the elderly and infirm who have difficulty in tolerating transplantation; 2. Those with keloid body, bleeding tendency, local or systemic infection; 3. Those with serious heart, liver, kidney, endocrine and other systemic diseases or suffering from immunodeficiency diseases and tumors; 4. Those who have been allergic to ultraviolet light in the past; 5. Those who have missed a visit or have had a serious adverse reaction during the course of treatment; 6. Other conditions that the investigator believes may be inappropriate for enrollment, such as the presence of increased risk to the subject or the presence of any condition that interferes with the results of the clinical trial.

Design outcomes

Primary

MeasureTime frame
Complex color area;

Secondary

MeasureTime frame
The time when the obvious effect appears;Safety observation;

Countries

China

Contacts

Public ContactYuanyuan Qu

People's Hospital of Xinjiang Uygur Autonomous Region

quyy711@163.com+86 187 9916 0608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026